Studies
Mega-CHOEP phase III is a randomised study comparing conventional chemoimmunotherapy with R-CHOEP-14 with high-dose chemotherapy plus Rituximab with autologous stem cell transplantation in high-risk patients aged 61 to 80 years with Aggressive Non-Hodgkin’s Lymphoma.
Submitter: René Hänsel
Investigation: MegaCHOEP Phase III
Resources: No Resources
Study type: Not specified
Baseline Data and Endpoints for MAXSEP
Submitter: René Hänsel
Investigation: MAXSEP
Resources: MAXSEP Trial Data, MAXSEP Trial Metadata
Study type: Not specified
Demographics, reference pathology diagnosis, Outcome (Event-free survival, Progression-free survival, Overall survival) Sample Size: 103
Submitter: René Hänsel
Investigation: Pegfilgrastim
Resources: Pegfilgrastim metadata, Pegfilgrastim trial data
Study type: Not specified
Demographics, reference pathology diagnosis, Outcome (Event-free survival, Progression-free survival, Overall survival)
Submitter: René Hänsel
Investigation: RICOVER-noRTh
Resources: RICOVER-noRTh metadata, RICOVER-noRTh trial data
Study type: Not specified
Demographics, reference pathology diagnosis, Outcome (Event-free survival, Progression-free survival, Overall survival)
Submitter: René Hänsel
Investigation: RICOVER-60
Resources: RICOVER-60 trial data, RICOVER-60 trial metadata
Study type: Not specified
Submitter: René Hänsel
Investigation: MInT
Resources: MInT trial data, MInt Trial Result Metadata
Study type: Not specified
Submitter: René Hänsel
Investigation: MegaCHOEP
Resources: MegaCHOEP Trial Metadata, MegaCHOEP trial data
Study type: Not specified
